Importancia de los títulos de anticuerpos antifosfolípidos no criterio entre pacientes con síndrome antifosfolípido primario y pacientes con lupus eritematoso sistémico

Urrego-Callejas, Tomás; Hernández, Alejandro; Giraldo, Sebastián Ruiz; Frade‐Sosa, Beatriz; Vanegas-García, Adriana L.; Muñoz, Camilo; Rúa, Carolina; Botero, Julieta Duque; González, Luis Alonso; Vásquez, Gloría; Gómez-Puerta, José A.

doi:10.1016/j.reuma.2022.07.003

Cited by 2 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a Latino population, we found the frequency of the lupus anticoagulant, 5.3%, to be higher than the 1 found in Hispanic patients from the LUMINA (lupus in minorities: nature versus nurture) cohort (2.0%–2.5%) and lower than in Mestizo patients from the GLADEL (Grupo Latino Americano de Estudio del Lupus) cohort (24.7%); of note, the frequency of IgM aCL antibodies in our cohort was also lower to the 1 reported in the GLADEL cohort (21.8% vs 42.6%) 7 ; that was also the case for IgG aCL antibodies, which was lower in our cohort (13.4% vs 48.7%) 16 . For aβ2GPI, antibodies that were not examined in the aforementioned studies, their frequency was higher than the 1 reported by Urrego-Callejas et al 17 : 15.0% for IgG and 10.0% for IgM. The differences in the prevalence of each antibody on these studies could be explained by differences in sample size, the techniques used to assess them, and/or the miscegenation of the populations studied.…”

Section: Discussioncontrasting

confidence: 58%

Unveiling the Link Between Antiphospholipid Antibodies and Cognitive Dysfunction in the Almenara Lupus Cohort

Velarde-Mejía,

Gamboa-Cárdenas,

Zevallos

et al. 2023

J Clin Rheumatol

View full text Add to dashboard Cite

Objective Cognitive dysfunction is a prevalent manifestation of systemic lupus erythematosus (SLE). There is evidence for the role of antiphospholipid (aPL) antibodies on its etiopathogenesis. Our objective was to identify the association between aPL antibodies and cognitive dysfunction in SLE patients. Methods This cross-sectional study included 135 patients evaluated from March 2015 to October 2017 at one center. Cognitive deficit was measured using the NEUROPSI test. Disease activity and damage were ascertained using the SLEDAI-2K (SLE Disease Activity Index 2000) and the SDI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), respectively; aPL antibodies were measured by enzyme-linked immunosorbent assay. The association between cognitive dysfunction and aPL antibodies was evaluated using univariable and multivariable linear regression models adjusted for age, sex, education, socioeconomic status, disease duration, SLEDAI-2K, SDI, mean current dose of prednisone, time of exposure to glucocorticoids, and drug use (immunosuppressants, hydroxychloroquine, aspirin, and warfarin). Results One hundred thirty-one patients (97.1%) were women; their mean (SD) age was 46.6 (12.5) years; 59 patients (43.7%) had positivity for at least 1 aPL antibody. IgM anticardiolipin (aCL) was positive in 24.5%, IgG in 13.5%, IgM aβ2GP1 in 16.8%, IgG anti-β2 glycoprotein in 24.6%, and the lupus anticoagulant in 5.3%. Ninety patients (66.7%) had some cognitive dysfunction. In the univariable analysis, a significant correlation between the NEUROPSI score and IgM aCL antibodies was found (B = −20.87 [SE, 3.2]; p < 0.001), which remained significant in the multivariable model (B = −13.89 [SE, 3.14]; p < 0.001). Conclusions IgM aCL antibodies are associated with cognitive dysfunction in patients with SLE. Larger and longitudinal studies are needed to assess the impact of these findings.

show abstract

Section: Discussioncontrasting

confidence: 58%

Unveiling the Link Between Antiphospholipid Antibodies and Cognitive Dysfunction in the Almenara Lupus Cohort

Velarde-Mejía,

Gamboa-Cárdenas,

Zevallos

et al. 2023

J Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…Even though the hypothesis that the non-criteria aPL profile could represent a distinguishing mark between the primary and secondary APS patients was raised, further studies are necessary to confirm this possible role of non-classical aPLs [29]. Our results did not show any significant differences between the titres of non-criteria aPLs in primary and secondary APS.…”

Section: Discussioncontrasting

confidence: 56%

Criteria and Non-Criteria Antiphospholipid Antibodies in Antiphospholipid Syndrome: How Strong Are They Correlated?

Caraiola,

Voicu,

Jurcut

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The place of non-criteria antiphospholipid antibodies (aPLs) in the diagnosis of antiphospholipid syndrome (APS) is still debatable. The aim of this research was to evaluate the correlations between the titres of non-criteria aPLs (anti-phosphatidylethanolamine (aPE), anti-phosphatidylserine (aPS), and anti-prothrombin (aPT) antibodies), and the ones of the already studied criteria aPLs (anti-cardiolipin (aCL) and anti-β2 glycoprotein I-aβ2GPI antibodies). Altogether, 72 APS (30 primary and 42 secondary) patients were included in our study. High correlation coefficients (rs) were found between aPS IgM and aCL IgM, overall (0.77, p < 0.01), as well as in the primary (0.81, p < 0.01), and secondary (0.75, p < 0.01) APS subgroups. Low or statistically insignificant correlations were observed between IgG/IgM isotypes of aPT and aCL, or aβ2GPI, in the entire study population, and when evaluating the subgroups. Therefore, moderate correlations were mainly identified between the tested non-criteria antibodies and the criteria ones, suggesting little added value for the use of the tested non-criteria aPLs, with the exception of aPT, which seems to have different kinetics and might be a promising APS diagnostic tool.

show abstract

Importancia de los títulos de anticuerpos antifosfolípidos no criterio entre pacientes con síndrome antifosfolípido primario y pacientes con lupus eritematoso sistémico

Cited by 2 publications

References 28 publications

Unveiling the Link Between Antiphospholipid Antibodies and Cognitive Dysfunction in the Almenara Lupus Cohort

Unveiling the Link Between Antiphospholipid Antibodies and Cognitive Dysfunction in the Almenara Lupus Cohort

Criteria and Non-Criteria Antiphospholipid Antibodies in Antiphospholipid Syndrome: How Strong Are They Correlated?

Contact Info

Product

Resources

About